Summarized by Masters of Longevity from Longevity Technology.
Reports that an AI-designed IPF drug produced proteomic-clock reductions and correlated functional improvements in a 12-week Phase IIa dataset, suggesting geroscience biomarkers in trials.
Key Takeaways
- Rentosertib, an AI-designed TNIK-targeting candidate, produced proteomic aging-clock reductions in treated patients.
- Twelve-week Olink proteomic data from 42 Phase IIa participants supported consistent age-reversal signals across six independent proteomic clocks.
- The trial showed a dose-dependent forced vital capacity improvement versus placebo that aligned with proteomic clock changes.
